New Thrivable 365 report reveals the patient stories behind GLP-1 persistence and the gaps life science companies must address to improve outcomes.
CLEVELAND, OH, JUNE 5, 2026 — Thrivable, a patient intelligence company serving the life science industry, today launched Thrivable 365 for the GLP-1 market, a quarterly syndicated research offering, with new research showing that mental health improvement—not weight loss—was the only statistically significant predictor of long-term GLP-1 adherence intent among patients using GLP-1s to manage diabetes. The finding comes from Thrivable 365’s inaugural report, In Their Own Words: Diabetes and GLP-1s — What Patient Stories Reveal About Their GLP-1 Journey, which analyzed 3,500 open-ended, audio-recorded responses from 591 current GLP-1 users across four stages of the treatment journey.
The report reveals that patients who persist on GLP-1s often do so while navigating meaningful gaps in the treatment experience: 60% arrived at prescribing with a neutral impression of GLP-1s; 66.5% of GLP-1 conversations were initiated by healthcare providers, with many described as short and transactional; and 75% of patients who experienced side effects simply “waited it out,” while only 5% mentioned adjusting their dose.
“Thrivable 365 findings show us that this is a story of patients who persist in spite of the system,” said David Edelman, Thrivable Founder & CEO. “These insights have direct implications for every company trying to improve initiation, adherence, and long-term outcomes in this space.”
Created to meet the needs of a GLP-1 market moving faster than traditional research was designed to match, Thrivable 365 is a quarterly syndicated research offering that gives pharmaceutical companies a continuous, affordable read on why patients behave the way they do.
Built on Thrivable’s highly engaged, 130,000+ triple-verified cardiometabolic patient panel, the offering delivers 80% of the patient insight pharma companies need for foundational research in roughly half the time and cost of a custom primary research study, with almost no internal lift. Each report draws on hundreds of GLP-1 patients—those living with and without diabetes—and combines closed-ended survey data, discrete choice conjoint analysis, and audio-recorded qualitative responses into a narrative designed to help brand, medical, and market access teams act quickly and confidently.
Unlike traditional syndicated research that stops at market-level metrics, Thrivable 365 reveals the patient-level “why” behind treatment decisions—combining conjoint analysis to quantify how patients weigh cost, efficacy, delivery, and tolerability with audio-recorded responses that deliver direct patient voice without requiring separate qualitative research.
For a glimpse into select findings from Thrivable 365, download the free white paper, Patients Who Persist: What Diabetes Patient Stories Reveal About the GLP-1 Treatment Journey.
Companies interested in Thrivable 365 for the GLP-1 market or bespoke cardiometabolic research can contact sales@thrivable.app or visit thrivable.app to schedule a call.
Thrivable is a patient intelligence company that helps life science organizations gain a competitive advantage through direct access to representative patient insights. With a 130,000+ triple-verified cardiometabolic patient panel and over 100 years of combined in-house healthcare research expertise, Thrivable delivers the speed and depth today’s market demands. Learn more at thrivable.app.